Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Target ID: TTDC00181

Target Information
NameProtein kinase C    
Type of targetClinical trial target    
DiseaseAmyotrophic lateral sclerosis
[ICD9: 335.20   ICD10: G12.2]
[1]
Cancer, unspecific
[ICD9: 140-229   ICD10: C00-C96]
[2]
Proteinuria-induced tubular injury[3]
Vascular disease
[ICD9: 325, 430-459   ICD10: G45-G46, I60-I95]
[4]
Drug(s)HO-0303Phase II/IIIDiabetic foot ulcers
AEB07Phase IITransplant therapeutics[5]
AEB071Phase IIPsoriasis
RottlerinPreclinicalParkinsoní»s Disease[6]
EC NumberEC 2.7.1.-
Related US Patent6,306,383
6,492,409
Target ValidationClick to Find Target Validation Information.    
InhibitorAEB07[5]
Calphostin C[7]
Go6850[8]
Go6976[9]
Rottlerin[6]
Staurosporine[7]
BinderSelenocompounds[2]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C. Neurobiol Dis. 2000 Aug;7(4):375-83. To Reference
Ref 2Protein kinase C as a molecular target for cancer prevention by selenocompounds. Nutr Cancer. 2001;40(1):55-63. To Reference
Ref 3Fatty acids carried on albumin modulate proximal tubular cell fibronectin production: a role for protein kinase C. Nephrol Dial Transplant. 2002 Oct;17(10):1751-7. To Reference
Ref 4Protein kinase C activation and its pharmacological inhibition in vascular disease. Vasc Med. 2000;5(3):173-85. To Reference
Ref 5What's next in the pipeline. Am J Transplant. 2008 Oct;8(10):1972-81. To Reference
Ref 6Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. To Reference
Ref 7Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines. J Neurooncol. 2000 Apr;47(2):109-15. To Reference
Ref 8Protein kinase epsilon dampens the secretory response of model intestinal epithelia during ischemia. Surgery. 2001 Aug;130(2):310-8. To Reference
Ref 9The protein kinase C inhibitor G?6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res. 2003 Jan 1;63(1):31-5. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543